Table 5.
Comorbidities associated with ESRD (dialysis-dependent) among OA patients undergoing THA.
| Comorbidity | ESRD + OA (N = 8,355a) | OA alone (N = 4,246,648a) | P-Value |
|---|---|---|---|
| Congestive heart failure | 1551 (18.6%) | 104854 (2.5%) | <0.0001 |
| Valvular disease | 735 (8.8%) | 166793 (3.9%) | <0.0001 |
| Pulmonary circulation disease | 297 (3.6%) | 34678 (0.8%) | <0.0001 |
| Peripheral vascular disease | 783 (9.4%) | 94376 (2.2%) | <0.0001 |
| Hypertension | 7730 (92.5%) | 2499692 (58.9%) | <0.0001 |
| Paralysis | 103 (1.2%) | 14454 (0.3%) | <0.0001 |
| Other neurological disorders | 619 (7.4%) | 160148 (3.8%) | <0.0001 |
| Chronic pulmonary disease | 1468 (17.6%) | 583334 (13.7%) | 0.0008 |
| Diabetes w/o chronic complications | 1896 (22.7%) | 547530 (12.9%) | <0.0001 |
| Diabetes w/chronic complications | 1177 (14.1%) | 41155 (1.0%) | <0.0001 |
| Hypothyroidism | 1374 (16.4%) | 572713 (13.5%) | 0.0127 |
| Renal failure | 8355 (100.0%) | 89558 (2.1%) | <0.0001 |
| Liver disease | 294 (3.5%) | 40063 (0.9%) | <0.0001 |
| Peptic ulcer Disease x bleeding | 10 (0.1%) | 654 (0.0%) | 0.0158 |
| Acquired immune deficiency syndrome | 50 (0.6%) | 3756 (0.1%) | <0.0001 |
| Lymphoma | 121 (1.5%) | 13337 (0.3%) | <0.0001 |
| Metastatic cancer | 0 (0.0%) | 6508 (0.2%) | <0.0001 |
| Solid tumor w/out metastasis | 34 (0.4%) | 18746 (0.4%) | 0.8679 |
| Rheumatoid arthritis/collagen vas | 612 (7.3%) | 157261 (3.7%) | <0.0001 |
| Coagulopathy | 671 (8.0%) | 90060 (2.1%) | <0.0001 |
| Obesity | 739 (8.9%) | 647089 (15.2%) | <0.0001 |
| Weight loss | 266 (3.2%) | 21096 (0.5%) | <0.0001 |
| Fluid and electrolyte disorders | 2324 (27.8%) | 368114 (8.7%) | <0.0001 |
| Chronic blood loss anemia | 242 (2.9%) | 73370 (1.7%) | 0.0106 |
| Deficiency Anemias | 4871 (58.3%) | 558656 (13.2%) | <0.0001 |
| Alcohol abuse | 37 (0.4%) | 62195 (1.5%) | 0.0036 |
| Drug abuse | 104 (1.2%) | 28901 (0.7%) | 0.0464 |
| Psychoses | 295 (3.5%) | 78170 (1.8%) | 0.0003 |
| Depression | 895 (10.7%) | 480056 (11.3%) | 0.5718 |
a
Sample size based on weighted frequencies.